NEU neuren pharmaceuticals limited

Ann: Appendix 4C - quarterly, page-21

  1. 6,288 Posts.
    lightbulb Created with Sketch. 22288
    Sillazze

    I don’t share your concerns.

    The good news is that this communication from the USPTO, dated 25 October, confirms that the NNZ-2591 patent has been allowed by the US Patent Office and is ready for issuance.

    However, the equivalent of a final patent proofreading has found three minor errors that need fixing first. These all relate to “drawing deficiencies”– for example, some drawings/figure numbers have been missed or are duplicated.

    As per the usual USPTO process, a deadline of two months has been given to correct these minor deficiencies, which, in my view, are the equivalent of typos. Really, a couple of days should be more than sufficient to fix the errors and return the paperwork.

    What is most important, in my view, is what is written on the front page of the correspondence from the USPTO – Notice of Allowance Mailed.
 
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)
Last
$12.96
Change
-0.140(1.07%)
Mkt cap ! $1.612B
Open High Low Value Volume
$13.20 $13.36 $12.82 $4.627M 354.8K

Buyers (Bids)

No. Vol. Price($)
1 7585 $12.96
 

Sellers (Offers)

Price($) Vol. No.
$13.03 3344 2
View Market Depth
Last trade - 16.10pm 16/06/2025 (20 minute delay) ?
NEU (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.